Drug intelligence / Profile preview

T1225

Development stage: Phase 3
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

T1225 is an investigational ophthalmic drug developed as a topical eye drop formulation for the treatment of bacterial conjunctivitis, including purulent bacterial conjunctivitis and trachoma. Clinical trials have compared the efficacy and safety of T1225 1.5% eye drops to standard treatments such as oral azithromycin and tobramycin eye drops in pediatric populations[2][3][4]. The precise mechanism of action or active ingredient for T1225 is not specified in available public sources, but it is used as an anti-infective agent in clinical studies targeting ocular bacterial infections.

Brand names: Azyter
Other names: azithromycin 1.5% ophthalmic solution

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on T1225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T1225.

Explore the full profile